Frequency and Prognostic Significance of P16(INK4A) Protein Overexpression and Transcriptionally Active Human Papillomavirus Infection in Laryngeal Squamous Cell Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2015 Feb 18

PMID 25688737

Citations 46

Authors

R J Young

D Urban

C Angel

J Corry

B Lyons

N Vallance

S Kleid

T A Iseli

B Solomon

D Rischin

Affiliations

Soon will be listed here.

Abstract

Background: Human papillomavirus (HPV) infection is a powerful prognostic biomarker in a subset of head and neck squamous cell carcinomas, specifically oropharyngeal cancers. However, the role of HPV in non-oropharyngeal sites, such as the larynx, remains unconfirmed.

Methods: We evaluated a cohort of 324 laryngeal squamous cell carcinoma (LSCC) patients for the expression of p16(INK4A) (p16) protein by immunohistochemistry (IHC) and for high-risk HPV E6 and E7 mRNA transcripts by RNA in situ hybridisation (ISH). p16 expression and HPV status were correlated with clinicopathological features and outcomes.

Results: Of 307 patients assessable for p16 IHC, 20 (6.5%) were p16 positive. Females and node-positive patients were more likely to be p16 positive (P<0.05). There were no other significant clinical or demographic differences between p16-positive and -negative cases. There was no difference in overall survival (OS) between p16-positive and -negative patients with 2-year survival of 79% in each group (HR=0.83, 95% CI 0.36-1.89, P=0.65). There was no statistically significant difference in failure-free survival (FFS) with 2-year FFS of 79% and 66% for p16-positive and -negative patients, respectively (HR=0.60, 95% CI 0.26-1.36, P=0.22). Only seven cases were found to be HPV RNA ISH positive, all of which were p16 IHC positive. There was no statistically significant difference in OS between patients with HPV RNA ISH-positive tumours compared with -negative tumours with 2-year survival of 86% and 71%, respectively (HR=0.76, 95% CI 0.23-2.5, P=0.65). The 2-year FFS was 86% and 59%, respectively (HR=0.62, 95% CI 0.19-2.03, P=0.43).

Conclusions: p16 overexpression is infrequent in LSCC and the proportion of cases with high-risk HPV transcripts is even lower. There are no statistically significant correlations between p16 IHC or HPV RNA ISH status and OS or disease outcomes.

Citing Articles

Predicting Early Death in Head and Neck Cancer-A Pilot Study.

Talani C, Olsson H, Roberg K, Wiechec E, Almangush A, Makitie A Cancers (Basel). 2025; 17(2).

PMID: 39858084 PMC: 11763563. DOI: 10.3390/cancers17020302.

Chromosomal instability increases radiation sensitivity.

Cosper P, Paracha M, Jones K, Hrycyniak L, Henderson L, Bryan A bioRxiv. 2024; .

PMID: 39345631 PMC: 11429890. DOI: 10.1101/2024.09.13.612942.

Oral and periodontal manifestation related during human papilloma virus infections: Update on early prognostic factors.

Amato M, Santonocito S, Bruno M, Polizzi A, Mastroianni A, Chaurasia A Heliyon. 2024; 10(10):e31061.

PMID: 38813162 PMC: 11133762. DOI: 10.1016/j.heliyon.2024.e31061.

p16 Expression in Laryngeal Squamous Cell Carcinoma: A Surrogate or Independent Prognostic Marker?.

Gallus R, Rizzo D, Rossi G, Mureddu L, Galli J, Artuso A Pathogens. 2024; 13(2).

PMID: 38392838 PMC: 10892421. DOI: 10.3390/pathogens13020100.

Updates on Larynx Cancer: Risk Factors and Oncogenesis.

Liberale C, Soloperto D, Marchioni A, Monzani D, Sacchetto L Int J Mol Sci. 2023; 24(16).

PMID: 37629093 PMC: 10454133. DOI: 10.3390/ijms241612913.

References

Halec G, Holzinger D, Schmitt M, Flechtenmacher C, Dyckhoff G, Lloveras B . Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma. Br J Cancer. 2013; 109(1):172-83. PMC: 3708587. DOI: 10.1038/bjc.2013.296. View

Isayeva T, Li Y, Maswahu D, Brandwein-Gensler M . Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol. 2012; 6 Suppl 1:S104-20. PMC: 3394168. DOI: 10.1007/s12105-012-0368-1. View

Gheit T, Abedi-Ardekani B, Carreira C, Missad C, Tommasino M, Torrente M . Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma. J Med Virol. 2013; 86(4):642-6. DOI: 10.1002/jmv.23866. View

Urban D, Corry J, Rischin D . What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?. Cancer. 2014; 120(10):1462-70. DOI: 10.1002/cncr.28595. View

Lim A, Do H, Young R, Wong S, Angel C, Collins M . Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. Int J Cancer. 2014; 135(4):887-95. DOI: 10.1002/ijc.28727. View

Omland T, Lie K, Akre H, Sandlie L, Jebsen P, Sandvik L . Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia. PLoS One. 2014; 9(6):e99114. PMC: 4053369. DOI: 10.1371/journal.pone.0099114. View

Chung C, Zhang Q, Kong C, Harris J, Fertig E, Harari P . p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 2014; 32(35):3930-8. PMC: 4251957. DOI: 10.1200/JCO.2013.54.5228. View

Weinberger P, Yu Z, Haffty B, Kowalski D, Harigopal M, Brandsma J . Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006; 24(5):736-47. DOI: 10.1200/JCO.2004.00.3335. View

Fakhry C, Westra W, Li S, Cmelak A, Ridge J, Pinto H . Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100(4):261-9. DOI: 10.1093/jnci/djn011. View

10.

Petti S . Lifestyle risk factors for oral cancer. Oral Oncol. 2008; 45(4-5):340-50. DOI: 10.1016/j.oraloncology.2008.05.018. View

11.

Baumann J, Cohen S, Evjen A, Law J, Vadivelu S, Attia A . Human papillomavirus in early laryngeal carcinoma. Laryngoscope. 2009; 119(8):1531-7. DOI: 10.1002/lary.20509. View

12.

Wolf G, Fisher S, Hong W, Hillman R, Spaulding M, Laramore G . Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324(24):1685-90. DOI: 10.1056/NEJM199106133242402. View

13.

Vlachtsis K, Nikolaou A, Markou K, Fountzilas G, Daniilidis I . Clinical and molecular prognostic factors in operable laryngeal cancer. Eur Arch Otorhinolaryngol. 2005; 262(11):890-8. DOI: 10.1007/s00405-005-0916-3. View

14.

Draganov P, Todorov S, Todorov I, Karchev T, Kalvatchev Z . Identification of HPV DNA in patients with juvenile-onset recurrent respiratory papillomatosis using SYBR Green real-time PCR. Int J Pediatr Otorhinolaryngol. 2005; 70(3):469-73. DOI: 10.1016/j.ijporl.2005.07.018. View

15.

Morshed K . Association between human papillomavirus infection and laryngeal squamous cell carcinoma. J Med Virol. 2010; 82(6):1017-23. DOI: 10.1002/jmv.21749. View

16.

Chung C, Gillison M . Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009; 15(22):6758-62. DOI: 10.1158/1078-0432.CCR-09-0784. View

17.

Wang H, Sun R, Lin H, Hu W . P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: consideration of some aspects. Cancer Sci. 2013; 104(12):1553-9. PMC: 7653521. DOI: 10.1111/cas.12287. View

18.

Ang K, Harris J, Wheeler R, Weber R, Rosenthal D, Nguyen-Tan P . Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1):24-35. PMC: 2943767. DOI: 10.1056/NEJMoa0912217. View

19.

Rischin D, Young R, Fisher R, Fox S, Le Q, Peters L . Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010; 28(27):4142-8. PMC: 2953971. DOI: 10.1200/JCO.2010.29.2904. View

20.

Morris L, Sikora A, Patel S, Hayes R, Ganly I . Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol. 2010; 29(6):739-46. PMC: 3056657. DOI: 10.1200/JCO.2010.31.8311. View